News & Insights
Besides sharing our hands-on expertise in projects, we regularly share industry insights, updates, and news. At NecstGen, we believe in sharing best practices to advance patient health. Together.
News
Stay up to date with the latest news, press releases and events here!
NecstGen Partners with Galapagos to Advance Decentralised CAR-T Cell Manufacturing in Europe
A collaboration to expand the decentralized cell therapy manufacturing network in Europe, advancing patient access.
NecstGen Delivers Consultancy to Advance Bone Regeneration Therapy
NecstGen provided expert consultancy to evaluate GMP manufacturing options for Dr. Debby Gawlitta’s MSC-derived spheroid therapy, advancing its path toward clinical translation in bone regeneration.
IPCEI-P-SMaRT project launch
This initiative will drive advancements in gene editing and gene therapy production platforms, bringing innovative therapies one step closer to patients in need of life-changing treatments.
RegMed XB U(iP)Scale project
Today at NecstGen, we had the pleasure of meeting with Assistant Professor Françoise Carlotti from Leiden University Medical Center to discuss our collaboration within the broader RegMed XB U(iP)Scale project, which recently received funding. A central goal of the...
Pan Cancer T announces clinical development and manufacturing with NecstGen
Pan Cancer T, a preclinical biotech specializing in TCR-T cell therapies, has expanded its partnership with Leiden-based CDMO NecstGen to include the clinical development and production of retroviral vectors. This collaboration will focus on developing a manufacturing and testing process for retroviral vectors, leveraging Pan Cancer T’s licensed stable producer technology.
OogFarma Partners with NecstGen for Ophthalmic Therapy.
This collaboration leverages NecstGen’s advanced GMP-compliant facilities to ensure safe and efficient delivery of anti-VEGF treatments for macular degeneration. Both companies share a mission to reduce healthcare costs while enhancing patient safety through innovative, ready-to-use medical solutions.
NecstGen Invites You To The CGT Circle
NecstGen is delighted to host a CGT Circle event on October 16th at our site in Leiden supporting the CGT Circle’s mission to harness the collective power and experience of women in the field of Cell and Gene Therapy.
€10 Million Awarded to NecstGen, NTrans Technologies, LUMC, and Divvly to Transform Cell and Gene Therapies
A grant from IPCEI Med4Health will facilitate the development of advanced technologies to improve cell and gene therapy production.
Press Release: NecstGen Recurring Customer Pan Cancer T Secures € 4.25 Million Seed Extension
NecstGen Recurring Customer Pan Cancer T secures 4.25 million Euro seed extension and continues its path to the clinic to treat solid tumors.
Collaboration UMC Utrecht for Bone Regeneration Therapy
NecstGen and UMC Utrecht partner to advance bone regeneration therapy using MSC-derived spheroids, marking a significant step in regenerative medicine.
EIC Awards €2.5 Million Grant
Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Council (EIC) for a significant grant of €2.5 million.
NecstGen and Aarhus University Collaborate in Groundbreaking Initiative for GMP-Compliant Stem Cell Production
NecstGen, Netherlands, a pioneering biotechnology center and non-profit CDMO specialising in Gene and Cell therapy, is proud to announce its groundbreaking collaboration with the Center for Gene and Cellular Therapy at Aarhus University Hospital (AUH), Denmark.
NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology
NecstGen and ProteoNic announce the successful development of improved lentiviral vectors for Cell and Gene Therapy, leveraging ProteoNic’s premium 2G UNic™ technology.
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
bioMérieux partners with NecstGen
bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
Webinars
At NecstGen, we are dedicated to driving innovation and knowledge-sharing in the fields of gene and cell therapy. Our webinar series is designed to provide in-depth insights into cutting-edge topics, including CAR T cell therapies and induced pluripotent stem cells (iPSCs), two of the most promising areas in modern medicine.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Stem Cells
Stem cells hold enormous potential for advancing regenerative medicine, with the ability to repair damaged tissues, treat degenerative diseases, and model complex conditions.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Ex Vivo Gene Therapy
Ex vivo gene therapy is one of the most promising areas in the fight against genetic disorders. By modifying cells outside the body and then reintroducing them into the patient, this approach ensures a high degree of control and precision.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
European Landscape For Cell & Gene Therapy companies
At NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start collaborations and partnerships so we can challenge today’s possibilities and enable the unthinkable, together.
Did you find what you were looking for?
If not, we would be happy to answer any questions you might have regarding our vacancies or life at NecstGen.
